Most cited papers from Eisai (United Kingdom)

Eisai (United Kingdom)

What are the most cited papers from Eisai (United Kingdom)?

The most cited paper from Eisai (United Kingdom) is "Lecanemab in Early Alzheimer’s Disease" (Christopher H. van Dyck, Chad J. Swanson, Paul S. S. Aisen et al., 2022), with 5,691 citations. Next come "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial" (5,578) and "Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer" (2,109).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 136 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Lecanemab in Early Alzheimer’s Disease Christopher H. van Dyck, Chad J. Swanson, Paul S. S. Aisen et al. · New England Journal of Medicine Open access	30 Nov 2022	5,691
2	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo et al. · The Lancet Open access	Mar 2018	5,578
3	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Martin Jean Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine Open access	11 Feb 2015	2,109
4	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access	13 Feb 2021	1,811
5	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet	Mar 2011	1,110
6	THE CELL BIOLOGY OF THE BLOOD-BRAIN BARRIER Lee L. Rubin, James M. Staddon · Annual Review of Neuroscience Review	Mar 1999	1,005
7	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Robert John Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology Open access	25 Oct 2015	957
8	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy Open access	17 Apr 2021	844
9	Occludin as a possible determinant of tight junction permeability in endothelial cells Tetsuaki Hirase, James M. Staddon, Mitinori Saitou et al. · Journal of Cell Science	15 Jul 1997	644
10	Dominant-Negative c-Jun Promotes Neuronal Survival by Reducing BIM Expression and Inhibiting Mitochondrial Cytochrome c Release Jonathan Richard Whitfield, Stephen J. Neame, Luc Paquet et al. · Neuron Open access	Mar 2001	565
11	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Theodore Sunki Hong et al. · Journal of Clinical Oncology Open access	15 Dec 2015	478
12	Autoimmune encephalomyelitis ameliorated by AMPA antagonists Terence Smith, Anthony Groom, Bin Zhu et al. · Nature Medicine	2000	468
13	Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons Andrea Watson, Andreas Eilers, Dominique Lallemand et al. · Journal of Neuroscience Open access	15 Jan 1998	366
14	Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy Jacqueline A. French, Gregory L. Krauss, Robert T. Wechsler et al. · Neurology Open access	22 Aug 2015	332
15	Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study Patricia Murphy, Margaret L. Moline, David W. Mayleben et al. · Journal of Clinical Sleep Medicine Open access	15 Nov 2017	329
16	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans Andrew J. Saykin et al. · Alzheimer s & Dementia Open access	Jul 2015	326
17	Clinical development of new drug–radiotherapy combinations on behalf of the NCRI CTRad Academia-Pharma Joint Working Group et al. · Nature Reviews Clinical Oncology ReviewOpen access	Jun 2016	321
18	PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons Alison Wood‐Kaczmar, Sonia Gandhi, Zhi Yao et al. · PLoS ONE Open access	17 Jun 2008	316
19	Evidence that tyrosine phosphorylation may increase tight junction permeability James M. Staddon, Kurt Herrenknecht, Caroline Smales et al. · Journal of Cell Science	Feb 1995	310
20	Regulation of Tight Junction Permeability and Occludin Phosphorylation by RhoA-p160ROCK-dependent and -independent Mechanisms Tetsuaki Hirase, Seinosuke Kawashima, Elaine Y.M. Wong et al. · Journal of Biological Chemistry Open access	Mar 2001	309
21	Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin et al. · Pain	9 Apr 2012	293
22	The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease Michael S. Rafii, Reisa Anne Sperling, Michael Donohue et al. · Alzheimer s & Dementia Open access	15 Aug 2022	290
23	Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons Andreas Eilers, Jonathan Richard Whitfield, Carol Babij et al. · Journal of Neuroscience Open access	Mar 1998	288
24	Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy Emilio Perucca, James C. Cloyd, David J.P. Critchley et al. · Epilepsia Open access	22 May 2008	261
25	c-Jun and the transcriptional control of neuronal apoptosis Jonathan Ham, Andreas Eilers, Jonathan Richard Whitfield et al. · Biochemical Pharmacology	Oct 2000	245
26	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi et al. · The Lancet Oncology	20 Sep 2011	244
27	N- Methyl- d -aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain Daniela Pohl, Petra Bittigau, Masahiko J. Ishimaru et al. · Proceedings of the National Academy of Sciences Open access	2 Mar 1999	244
28	Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor Hachiro Sugimoto, Hiroo Ogura, Yasuo Arai et al. · The Japanese Journal of Pharmacology Open access	2002	240
29	On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers Annemiek Vermeeren, Stefan Jongen, Patricia Murphy et al. · SLEEP Open access	31 Dec 2018	228
30	Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study Martin Rhys Farlow, Stephen Salloway, Pierre N. Tariot et al. · Clinical Therapeutics Open access	Jul 2010	217
31	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Aurélien Marabelle et al. · Annals of Oncology Open access	6 Oct 2018	216
32	Gini Coefficient: A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases Piotr P. Graczyk · Journal of Medicinal Chemistry	19 Oct 2007	216
33	Bax promotes neuronal cell death and is downregulated during the development of the nervous system Konstantinos Vekrellis, Mary Jane McCarthy, Andrea Watson et al. · Development	15 Mar 1997	214
34	The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts Stefan Cano, Holly B. Posner, Margaret L. Moline et al. · Journal of Neurology Neurosurgery & Psychiatry Open access	29 Sep 2010	211
35	Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study Bruno Dubois, EDUARDO S. TOLOSA, Regina Katzenschlager et al. · Movement Disorders	22 Aug 2012	201
36	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations Shannon M. Smith et al. · Pain Open access	8 Jun 2020	197
37	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study Chung‐Han Lee et al. · The Lancet Oncology Open access	15 Jun 2021	189
38	A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours David S. Boss, Hilary Glen, Jos H. Beijnen et al. · British Journal of Cancer Open access	19 Apr 2012	187
39	Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial Michel Baulac, Martin J. Brodie, Anna R. Patten et al. · The Lancet Neurology	7 Jun 2012	187
40	Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets Thomas Briston, David L. Selwood, György Szabadkai et al. · Trends in Pharmacological Sciences ReviewOpen access	6 Dec 2018	186
41	Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2 Mikko Kärppä, Jane Yardley, Kate Pinner et al. · SLEEP Open access	25 Jun 2020	178
42	Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Robert John Motzer et al. · Journal of Clinical Oncology Open access241 authors	16 Jan 2024	176
43	Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats Susumu Kotani, T. Yamauchi, Takashi Teramoto et al. · Neuroscience	7 Aug 2006	174
44	Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease Lawrence S. Honig, Marwan Noel Sabbagh, Christopher H. van Dyck et al. · Alzheimer s Research & Therapy Open access	10 May 2024	172
45	Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis Pablo Garcia-Reitboeck, Alexandra E. M. Phillips, Thomas M. Piers et al. · Cell Reports Open access	Aug 2018	171
46	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization Tatiana D. Papkovskaia, Kai‐Yin Chau, Francisco Iñesta-Vaquera et al. · Human Molecular Genetics Open access	23 Jun 2012	164
47	Glutamate Receptor Expression in Multiple Sclerosis Lesions Jia Newcombe, A.B.M. Sharif Hossain Musamma M. Uddin, Rosamund E. Dove et al. · Brain Pathology Open access	9 Oct 2007	161
48	Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 Vicky Makker et al. · Journal of Clinical Oncology Open access	14 Apr 2023	156
49	Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux disease Dekkers, Beker, Thjodleifsson et al. · Alimentary Pharmacology & Therapeutics Open access	1999	156
50	Mitochondrial permeability transition pore: sensitivity to opening and mechanistic dependence on substrate availability Thomas Briston, Malcolm C. Roberts, Siân Lewis et al. · Scientific Reports Open access	30 Aug 2017	154

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.